Almirall & Forest Announce Positive Results from the ATTAIN Phase III Study of Aclidinium Bromide & the Phase IIb Studies wit...
January 04 2011 - 3:45PM
Business Wire
Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE:
FRX) today announced positive top-line results of ATTAIN, a six
month double-blind placebo-controlled pivotal Phase III study
comparing the efficacy and safety of inhaled aclidinium bromide
200μg and 400μg twice daily (BID) versus placebo, in 828 patients
with moderate to severe COPD.
Aclidinium 200µg and 400µg produced statistically significant
increases from baseline in morning pre-dose (trough) FEV1 versus
placebo at week 24 (99mL and 128mL, respectively; p
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024